Ukutholwa Kokuqala Ngokusebenzisa i-Ultrasound Kudlala indima ebalulekile
Kungenzeka ukuthi wena noma othandekayo unesifo somdlavuza we-thyroid ngemuva kokuthola ukuqhuma noma ukuvuvukala entanyeni yakho. Ngaphandle kwalokho, udokotela wakho kungenzeka ukuthi uthole isici ngesikhathi sokuhlolwa komzimba njalo noma kwenzeka ngesikhathi se-ultrasound yesakhiwo esiseduze ne- thyroid (njengamarridi wakho we-carotid).
I-Cancer Yegciwane Ekukhuphukeni
Ngokusho kwe-American Cancer Society, cishe abantu abayizinkulungwane ezingu-54 bazokwakha umdlavuza we-thyroid e-United States ngonyaka ozayo, futhi le nombolo ikhulile eminyakeni yamuva.
Eqinisweni, umdlavuza we-thyroid ngumdlavuza okhulayo kakhulu e-United States .
"Kungani" ngemuva kokwanda komdlavuza we-thyroid kungase kube ngokuphindaphindiwe, ngokusho kwesifundo kuJAMA . Isizathu esiyinhloko sokunyuka komdlavuza wegciwane kungachazwa ngokusetshenziswa okwandisiwe kwe-thyroid ultrasound, engabona ama-nodules amancane we- thyroid okungenzeka angatholakali esikhathini esidlule.
Ngamanye amazwi, ukuxilongwa ngokweqile kuyinkinga, njengoba amasu okucabanga (njenge-ultrasound) kanye nama-biopsies afisa ama-needle amahle athole izicubu ezincane ze-thyroid (<2cm) ezazingenayo indolent noma ezingakhathazeki ngesikhathi (ezingabangela izimpawu ngokushesha noma isidingo sokwelashwa) .
Esinye isizathu, nakuba esincane ngokucwaninga kwe- JAMA , inguquko engenzeka ekuboniseni izinto ezinobungozi ezifana nokukhuluphala nokubhema okungeyona ndawo. Ukwehliswa kwemvelo kwamakhemikhali afana ne-pesticides ne-bisphenol A nakho kungadlala indima, nakuba ubufakazi besayense obuxhumanisa nokutholakala kulezi zinhlobo zamakhemikhali ngengozi yomdlavuza we-thyroid bukhulu.
Ukubikezelwa kweCarry Thyroid
Kubalulekile ukuqaphela ukuthi ngenkathi amacala omdlavuza we-thyroid ekhulile eminyakeni yamuva, izinga lokufa lomdlavuza we -roid liye lahlala liqinile. Eqinisweni, izinga lokufa (cishe abangaba ngu-2 000 abafa ngomdlavuza wesibeletho) liphansi kakhulu, uma kuqhathaniswa nezinye izinhlobo zomdlavuza.
Okubalulekile ukuthi ukuchazwa kwezifo zomdlavuza ezivamile kakhulu (umuthi womuthi we-papillary ne-follicular we-thyroid) kuhle kakhulu.
Ake sibheke ngokucophelela izibalo zokuphila zomdlavuza wegciwane le-papillary, okuyizinhlobo ezivame kakhulu zomdlavuza wegciwane, ezenzeka cishe ezingamaphesenti angu-80 azo zonke izimo.
Ukusinda Izibalo Ze-Papillary Cancer Cancer
Izinga lokusinda iminyaka engu-5 (ithuba lokuphila okungenani iminyaka emihlanu emva kokuthola ukuthi ukhona) cishe amaphesenti angu-100 abantu ababhekene nomdlavuza we-thyroid we-papillary olinganiselwe kumgogodla wegciwane.
Yiqiniso, njengoba umdlavuza we-papillary we-thyroid usakazeka kuma-lymph nodes, izicubu ezizungezile, nezicubu, noma ngisho nezitho ezikude, amazinga okusinda ayancipha. Eqinisweni, ngokusho kokucwaninga ku- JAMA, kunezinga elikhulayo lokufa ngenxa yomdlavuza we-papillary wegciwane eminyakeni eyishumi edlule.
Gcina engqondweni lezi zinombolo izibalo; ababikezeli ithuba lomuntu oyedwa lokusinda.
Khumbula, izinga lokusinda iminyaka emihlanu libukeka kuphela eminyakeni emihlanu emva kokuxilongwa. Kukhona ithuba elihle kakhulu umuntu otholakala enomdlavuza we-thyroid ehlala iminyaka engaphezu kwengu-5. Eqinisweni, ukufa komdlavuza wegciwane lesandulela ngculazi esiteshini sesigaba I kuyinto engavamile kakhulu.
Izwi elivela
Ngenkathi eshaqisayo futhi esabisa ukubona ukukhula komdlavuza wegciwane lesibindi, kubalulekile ukuqonda ukuthi okuningi kwalokhu kungabhekiswa ekusetshenzisweni okuqhubekayo kwamasu okuxilonga. Ilungelo lakho lokusinda emdlalweni wekhanda we-thyroid lihle kakhulu, ngakho-ke qhubeka usebenza kahle empilweni yakho bese ubuza imibuzo eminingi njengoba ukwelashwa komdlavuza wakho kusebenza.
> Imithombo:
> I-American Cancer Society. (2018). Izibalo Eziyinhloko Ze-Cancer Yegciwane.
> I-American Thyroid Association. (nd). I-Cancer Cancer (Papillary and Follicular).
> Lim H, Devesa SS, Sosa JA, Hlola D, Kitahara CM. Amathrendi ekwenzeni umdlavuza we-Thyroid kanye nokufa e-United States, ngo-1974-2013. I-JAMA 2017 Apr 4; 317 (13): 1338-48.